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Abstract
Background: The ACE gene contains a polymorphism consisting of either the presence (insertion,
I) or absence (deletion, D) of a 287 bp alu repeat in intron 16. The D allele is associated with
increased ACE activity in both tissue and plasma. The DD genotype is associated with risk of
developing ARDS and mortality. The frequency of the D allele is higher in patients with pulmonary
fibrosis, sarcoidosis and berylliosis. The role of this polymorphism has not been studied in the
development of BPD in the premature newborn.
Methods: ACE I/D genotype was determined in 245 (194 African-American, 47 Caucasian and 4
Hispanic) mechanically ventilated infants weighing less than 1250 grams at birth and compared to
outcome (death and/or development of BPD).
Results: The incidence of the D allele in the study population was 0.58. Eighty-eight (35.9%) infants
were homozygous DD, 107 (43.7%) were heterozygous ID and 50 (20.4%) were homozygous II.
There were no significant differences between genotype groups with respect to ethnic origin, birth
weight, gestation, or gender. There was no effect of the ACE I/D polymorphism on mortality or
development of BPD (O2 on 28 days or 36 weeks PCA). Secondary outcomes (intraventricular
hemorrhage and periventricular leukomalacia) similarly were not influenced by the ACE ID
polymorphism.
Conclusions: The ACE I/D polymorphism does not significantly influence the development of BPD
in ventilated infants less than 1250 grams.
Background
Prematurely born infants who require mechanical ventila-
tion (MV) frequently develop chronic lung disease known
as bronchopulmonary dysplasia (BPD). Oxidant injury,
mechanical disruption of the lung, inflammation and
subsequent failure of lung development are considered
the major mechanisms in the pathogenesis of BPD. The
development of BPD is characterized by an initial acute
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inflammatory component followed by variable degrees of
lung fibrosis and failure of alveolar septation, both of
which ultimately impair the development of the imma-
ture lung [1-5]. The inflammatory component, which
consists interstitial and alveolar edema, hyaline mem-
brane formation, epithelial cell necrosis and influx of acti-
vated neutrophils, is similar (albeit not identical) to that
seen in other forms of acute lung injury (ALl).
There is increasing evidence to support the role for the
activation of the renin-angiotensin system (RAS) system
during ALI. In ARDS there is an increase in bronchoalveo-
lar lavage and a concomitant decrease in circulating angi-
otensin converting enzyme (ACE) activity[6,7]. This
increase in local ACE activity may influence the course of
acute lung injury by its effects on vascular permeability,
epithelial cell survival and fibroblast activity [8-12]. Angi-
otensin-II (AT-II) concentrations are increased in patients
with ARDS, consistent with activation of the RAS with
ALI[13]. Inhibition of AT-II with type 1 angiotensin recep-
tor antagonists delayed the onset of ARDS and inhibited
neutrophil influx in to the lung in experimental mod-
els[14]. The role of RAS activation in the lungs of prema-
ture infants with respiratory distress syndrome and its
evolution into BPD has not been determined.
There is significant variation in circulating ACE activity
among individuals, which may be genetically determined.
The human ACE gene is located on chromosome 17
(17q23) and contains a polymorphism consisting of
either the presence (insertion, I) or absence (deletion, D)
of a 287 bp alu repeat in intron 16[15]. The deletion is
associated with increased ACE activity in both tissue and
in the circulation and accounts for about 47% of the intra-
individual variation in plasma ACE activity in Cauca-
sians[15,16]. A role for genetic variation in ACE activity in
both acute and chronic lung disease has recently been sug-
gested [17-21]. Higher intrinsic ACE activity (DD geno-
type) is associated with an increased risk of developing
ARDS and other lung diseases [17-21]. The potential role
of this polymorphism to influence risk of developing
chronic lung disease has not been studied in the prema-
ture newborn.
Because of the relationship between inflammation and
activation of the RAS and the association with lung fibro-
sis and adverse outcome in ARDS, the ACE l/D polymor-
phism may modify risk for the development of chronic
lung disease or death in mechanically ventilated VLBW
infants. The purpose of this study was to determine if
there is a relationship between the ACE I/D polymor-
phism and respiratory outcomes of death or the develop-
ment of BPD, in mechanically ventilated very low birth
weight (VLBW) infants.
Methods
Genomic DNA used for this case controlled study was
extracted from archival tracheal aspirate (TA) pellets (223
patients) or blood (22 patients) collected prospectively as
part of an ongoing study of genetic factors in the develop-
ment of complications of prematurity. The TAs that were
used as a source of genomic DNA were originally collected
as part of long term longitudinal studies examining
cytokine concentrations and the development of
CLD[22,23]. Infants were included in this study if they
fulfilled the following inclusion criteria: birth weight less
than 1250 grams, mechanical ventilation (MV) during the
first week of life, complete clinical data on pulmonary
outcome and a genomic DNA sample that could be used
for genotyping. Infants were excluded if complete data on
pulmonary outcome was not available or suitable DNA
was not available. The study was approved by the Institu-
tional Review Board for Human Research at Louisiana
State University Health Sciences Center in Shreveport.
Cultures for genital mycoplasmas were performed on
samples collected in the first few days of life. Clinical and
outcome data were abstracted from the clinical record and
included information on respiratory outcome, survival
and development of complications of prematurity.
Laboratory methods
DNA isolation
Isolation of total DNA from blood or TA pellets was per-
formed using the QIAmp DNA Mini kits™ (Qiagen Incor-
porated, Chatsworth, CA). Briefly, TA pellets were
suspended in 200 µl of sterile phosphate buffered saline
by vigorous vortexing, then digested in proteinase K and
applied to silica gel spin columns. Columns were washed
in the manufacturer's supplied buffers and the total DNA
was eluted in 200 µl elution buffer. Blood (200 µl) was
extracted similarly to the TA pellets.
ACE I/D genotyping
ACE I/D polymorphism was performed by microplate
PCR method as described previously[24]. (Primers used
in the assay: 5'-CTG GAG ACC ACT CCC ATC CTT TCT-3'
AND 5'-GAT GTG GCC ATC ACA TTC GTC AGA T-3'. In
10 microliter PCR volume, the following components
were added with the final concentration of MgCl2 1.5 mM,
KCl 50 mM, 5%DMSO, Triton X-100 0.1%, 200 micro-
molar each of dNTPs, 10 pmol each primer, 1–2 U of Taq
polymerase, and 1 microliter of DNA. DNA was dena-
tured at 95°C for 5–10 min, followed by 30 cycles of
denaturation at 94° for 60 sec, annealing at 67 for 60 sec,
and extension at 72° for 2 minutes, with a final extension
at 72° for 7 min. PCR products were separated on 2% aga-
rose gel containing 0.5-microgram/ml ethidium bromide.
After gel electrophoresis the bands were visualized by UV-
transillumination. The PCR product is a 190 bp fragmentBMC Pediatrics 2004, 4:26 http://www.biomedcentral.com/1471-2431/4/26
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in the absence of the insertion (D genotype) and a 490 bp
fragment in the presence of the insertion (I genotype).
Data analysis
Several definitions of BPD have been used through the
years. Initially BPD was defined as oxygen dependency at
28 days of age[25,26]. More recently, the use of oxygen
dependency at 36 weeks postconceptional age (PCA) has
been proposed as a more suitable definition of BPD.[27]
Both definitions of BPD predict long term respiratory
abnormalities. Data analysis consisted of comparing the
frequencies of the ACE I/D genotypes in infants with and
without the outcome of interest (supplemental oxygen
administration at 28 days or 36 weeks PCA, death or BPD
/death before 36 weeks PCA) by Chi Square. All statistical
analysis was performed using the SPSS for Windows ver-
sion 12.0 (SPSS Inc., Chicago, IL). The Student t-test was
used to assess normally distributed variables. The Wilcox
Rank Sum test was used for analysis of factors that were
not normally distributed. A probability value of less than
0.05 was considered statistically significant. The data are
presented as mean ± standard error of the mean (SEM).
Results
Two hundred and forty five (245) patients had complete
clinical information on respiratory outcome and genomic
DNA available for genotyping. Mean gestational age and
birth weight of the study population was 26.4 ± 0.1 weeks
and 869 ± 12 grams respectively. One hundred and
ninety-four (79%) infants were African-American, 47 (19
%) were Caucasian and 4 (2%) were Hispanic. Male:
female ratio was 147:98. All patients required MV at birth
and 228 (93%) infants were treated with exogenous sur-
factant therapy (Survanta®, Ross Products Division,
Abbott Laboratories, Columbus, OH). Tracheal aspirate
cultures obtained during the first few days of life grew Ure-
aplasma urealyticum (Uu) on at least one occasion from 74
of 217 infants cultured (34%) and Mycoplasma hominis
(Mh) from 29 (13%). One hundred and fifty one (67%)
infants were oxygen dependent at 28 days and 55 (25%)
were oxygen dependent at 36 weeks PCA. There were 39
(16%) patients who died (from all causes) during their
initial hospitalization (24 before 28 days of age and 15
after 28 days).
All 243 infants were genotyped for the ACE I/D polymor-
phism. The frequency of the D allele in the study popula-
tion was 0.58. The frequency of the D allele was similar
between African-American (0.57) and Caucasian infants
(0.59) (p = 0.664). Fifty (20.4%) infants were
homozygous II, 107 (43.7 %) were heterozygous ID and
88 (35.9%) were homozygous DD.
Baseline clinical characteristics of birth weight, gestational
age, race, gender, TA isolation of Mh, and the need for sur-
factant replacement were not different between genotype
groups (Table 1). Isolation of Ureaplasma urealyticum
from the trachea was more frequent in Caucasian infants
who had the ACE II genotype (II 55%, ID 9%, DD 22%; p
= 0.046). Uu isolation frequencies were similar between
genotype groups in African-American infants. Baseline
clinical characteristics for Caucasian and African-Ameri-
can infants separately can be found in the online
supplement.
Clinical characteristics of surviving infants who were or
were not oxygen dependent at days are shown in Table 2.
Infants who were oxygen dependent at 28 days were less
mature, of lower birthweight, more likely to have TA iso-
lation of Uu or Mh, and more likely to have received sur-
factant replacement therapy than those weaned from
oxygen by 28 days of age. Ethnic groups and gender were
not different between outcome groups. Infants who died
or who were oxygen dependent at 36 weeks PCA (BPD)
Table 1: Baseline Clinical Characteristics
ACE Genotype
II (n = 50) ID (n = 107) DD (n = 88) P value
Birth Weight 874 ± 29 876 ± 18 858 ± 20 0.793
Gestation 26.4 ± 0.3 26.5 ± 0.2 26.2 ± 0.2 0.386
Race (Caucasian) 11 (22) 17(16) 19 (22) 0.664
Gender (Males) 28 (56) 59 (55) 59 (67) 0.166
Uu isolated from TAa 18/46 (39) 29/88 (33) 27/83 (33) 0.719
Mh isolated from TAa 4/46 (9) 14/88 (16) 11/83 (13) 0.507
Surfactant Replacement 48 (96) 99 (93) 81 (92) 0.651
Data are presented as Mean ± Standard error of Mean. Numbers in parenthesis represent percentages.
aNot all infants had TA cultures performed for Uu and Mh
Uu Ureaplasma urealyticum
Mh Mycoplasma hominis
TA Tracheal AspirateBMC Pediatrics 2004, 4:26 http://www.biomedcentral.com/1471-2431/4/26
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were similarly less mature, of lower birthweight, and were
more likely to have received surfactant replacement ther-
apy than surviving infants without BPD (Table 3). Isola-
tion of either Uu or Mh from the TA had no influence on
this outcome.
Because the ACE I/D polymorphism may have different
functional effects on plasma and tissue ACE activities in
different ethnic groups, we analyzed the effects of ACE on
the incidence of BPD separately for Caucasian and Afri-
can-American infants. (The effects of the ACE I/D poly-
morphism on the incidence of BPD and other outcomes
for the combined group can be found in the online data
supplement). Table 4 shows the effects of ACE genotype
on outcomes in ventilated Caucasian infants less than
1250 grams. There was no significant effect of ACE geno-
type on mortality, oxygen dependency at either 28 days or
36 weeks PCA or the combined outcome of death or BPD.
The incidence of periventricular leukomalacia (PVL) was
significantly higher in Caucasian infants with the II geno-
type. The incidence and severity of intraventricular hem-
orrhage (IVH) was not affected by ACE genotype.
The effects of ACE genotype on outcome in ventilated
African-American infants less than 1250 grams are shown
in Table 5. There was no significant effect of ACE genotype
on mortality, oxygen dependency at either 28 days or 36
weeks PCA or the combined outcome of death or BPD.
The incidence of PVL was not affected by ACE genotype in
African-American infants. Similar to that observed in Cau-
casian infants, there was no apparent effect of the ACE I/
D polymorphism on the incidence and severity of IVH in
African American infants.
Table 2: Comparison of Infants Oxygen Dependent at 28 days
No Oxygen at 28 days (n = 75) Oxygen at 28 days (n = 151) P value
Gestation (weeks) 27.4 ± 0.1 26.0 ± 0.1 <0.001
Birth Weight (grams) 996 ± 18 826 ± 14 <0.001
Race (Caucasian) 20 (27) 26 (17) 0.103
Gender (Males) 39 (52) 95 (63) 0.102
Surfactant therapy 75 (87) 144 (95) 0.020
Ureaplasma isolateda 16/67 (24) 55/134 (41) 0.016
Mycoplasma isolateda 4/67 (6) 23/134 (17) 0.028
IVHb 8/74 (11) 55/151 (36) <0.001
IVH = Grade 3b 4/74 (5) 35/151 (23) <0.001
PVLb 2/74 (3) 15/151 (10) 0.054
Data are presented as Mean ± Standard error of Mean. Numbers in parenthesis represent percentages.
aNot all infants had TA cultures performed for Uu and Mh
bNot all infants had cranial US evaluations
Uu Ureaplasma urealyticum Mh Mycoplasma hominis IVH Intraventricular Hemorrhage PVL Periventricular leukomalacia TA Tracheal Aspirate
Table 3: Clinical Characteristics of Infants who Died or Developed BPD
Survival without BPD (n = 162) Death or BPD (n = 83) P value
Gestation (weeks) 26.6 ± 0.1 25.8 ± 0.2 <0.001
Birth Weight (grams) 925 ± 14 760 ± 17 <0.001
Race (Caucasian) 33 (20) 14 (17) 0.737
Gender (Males) 96 (60) 50 (60) 0.926
Surfactant therapy 147 (91) 81 (98) 0.046
Ureaplasma isolateda 49/144 (34) 25/73 (34) 0.974
Mycoplasma isolateda 20/144 (14) 9/64 (12) 0.750
IVHb 31/161 (19) 41/80 (52) <0.001
IVH = Grade 3b 15/161 (9) 31/80 (39) <0.001
PVLb 8/161 (5) 10/80 (13) 0.033
Data are presented as Mean ± Standard error of Mean. Numbers in parenthesis represent percentages.
aNot all infants had TA cultures performed for Uu and Mh
bNot all infants had cranial US evaluations
Uu Ureaplasma urealyticum Mh Mycoplasma hominis IVH Intraventricular Hemorrhage PVL Periventricular leukomalacia TA Tracheal AspirateBMC Pediatrics 2004, 4:26 http://www.biomedcentral.com/1471-2431/4/26
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Since birth weight and gestation are the primary determi-
nants of adverse outcome, analysis was repeated in both
infants greater than 750 grams and infants ≤ 750 grams.
There was no significant effect of ACE genotype when this
subgroup analysis was performed (data not shown).
Discussion
The RAS is activated during lung injury and plays a role in
several pathological processes. In addition to the pulmo-
nary endothelium, respiratory epithelium also possesses
significant ACE activity. Fas-induced alveolar epithelial
cell apoptosis is dependent on local AT-II production and
interaction with it receptor.[10,11] Further, AT-II is
mitogenic for lung fibroblasts and aberrant AT-II produc-
tion has been linked with some forms of pulmonary fibro-
sis[12,18,28-30]. Inhibition of AT-II with type 1
angiotensin receptor antagonists delayed the onset of
ARDS and inhibited neutrophil influx into the lung in
experimental models[14]. In adults, there is an increase in
bronchoalveolar lavage ACE activity and AT-II during ALI,
however the contribution of activation of the RAS to neo-
natal lung injury has received little study[6,13].
The frequency of the D allele in our study population was
not different than reported in our local population or for
other groups[16,24,31]. The ACE D allele is common with
a frequency approximately 50–60% in Caucasians and
60–65% in African-Americans. This suggests that the D
allele is neither a risk factor nor a protective factor for
either premature birth or the need for mechanical ventila-
tion. We did not study early cardiovascular adaptation or
record measures of early illness severity, as did Harding et
al[32] In that study the DD genotype was associated with
a worse cardiovascular adaptation. In our study, the
infants are much more immature, of lower gestational age
and almost universally had hyaline membrane disease.
In our study population, the ACE ID polymorphism was
not associated with an altered risk for the development of
BPD, oxygen dependency at 28 days, death (early, late or
Table 4: Effect of ACE genotype on Outcomes in Caucasian Infants
ACE Genotype
II (n = 11) ID (n = 17) DD (n = 19) P value
Oxygen at 28 days 6/11 (55) 10/15 (67) 9/18 (47) 0.620
Oxygen at 36 weeks PCA 3/10 (30) 4/15 (27) 3/18 (17) 0.674
Death <28 days 0 (0) 1 (16) 1 (5) 0.724
Death or Oxygen at 36 weeks 4 (36) 6 (35) 4 (21) 0.558
Death ≥ 28 days 3 (27) 1 (6) 0 (0) 0.039
IVHa 2/10 (20) 6/17 (35) 1/19 (5) 0.076
IVH ≥ Grade 3a 2/10 (20) 3/17 (18) 1/19 (5) 0.415
PVLa 3/10 (30) 0/17 (0) 1/19 (5) 0.022
Numbers in parenthesis represent percentages.
aNot all infants had cranial US evaluations
PCA Postconceptional age IVH Intraventricular Hemorrhage PVL Periventricular leukomalacia
Table 5: Effect of ACE genotype on Outcomes in African-American Infants
ACE Genotype
II (n = 39) ID (n = 88) DD (n = 66) P value
Oxygen at 28 days 24/36 (67) 57/82 (70) 43/59 (73) 0.805
Oxygen at 36 weeks PCA 7/34 (21) 22/79 (28) 16/58 (28) 0.698
Death <28 days 3 (8) 6 (7) 8 (12) 0.517
Death or Oxygen at 36 weeks 12 (31) 31 (35) 25 (37) 0.792
Death ≥ 28 days 3 (8) 7 (9) 4 (7) 0.925
IVHa 14/38 (37) 23/86 (27) 25/67 (37) 0.311
IVH ≥ Grade 3a 7/38 (18) 15/86 (17) 17/67 (25) 0.438
PVLa 1/38 (3) 5/86 (6) 8 (12) 0.145
Numbers in parenthesis represent percentages.
aNot all infants had cranial US evaluations
PCA Postconceptional age IVH Intraventricular Hemorrhage PVL Periventricular leukomalaciaBMC Pediatrics 2004, 4:26 http://www.biomedcentral.com/1471-2431/4/26
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total mortality) or composite outcomes (BPD or death)
suggesting that factors other than genetic variation at this
locus contribute to these outcomes. This is in contrast to
that seen in adults with ARDS or other lung disorders such
as pulmonary fibrosis, sarcoidosis and berylliosis where
the D allele is associated with disease [18-21].
Indeed genetic factors may not have a large influence in a
disease (BPD) where maturity at birth has such an over-
whelming influence. Our previous study in this popula-
tion failed to find any association of the tumor necrosis
factor-α-308 G/A, MCP-1-2518 A/G or transforming
growth factor-β1 +915 G/C SNPs on the development of
BPD[33] Additionally we have found that the IL-10-1082
G/A SNP has no effect on the incidence of BPD (Yana-
mandra et al, Pediatric Pulmonology, in press).
The finding of increased incidence of PVL in Caucasian
infants with the II genotype may be due more to the
greatly increased incidence of Ureaplasma urealyticum col-
onization in these infants. Chorioamnionitis, which is
highly correlated with isolation of Uu, is a risk factor for
PVL.[34] Because of the retrospective nature of this study
we were not able to systematically review placental
pathology.
Our study has several limitations. The ACE I/D polymor-
phism has only been demonstrated to be functional in
Caucasians.[16] Data linking this polymorphism and
ACE activity in other ethnic groups are either lacking or
suggests the polymorphism is non functional (African-
Americans)[31]. If this were true, then one would expect
to find no effect of the ACE I/D polymorphism on out-
comes in African-American infants. The numbers of Cau-
casian infants in this study are few and an effect of the
ACE I/D polymorphism on the incidence of chronic lung
disease or other outcomes may not be detected. Thus it
may be relevant to examine the contribution of the ACE I/
D polymorphism to chronic lung disease in a larger
cohort of Caucasian infants.
The observations of this retrospective case controlled
study are also limited somewhat by selection bias.
Because only infants who were mechanically ventilated
were included, the true impact of this polymorphism on
the complications of prematurity may be underestimated.
Since this was a retrospective study using stored material
no attempt was made to correlate phenotype with geno-
type (ie TA ACE measurements).
Lung injury and the subsequent maladaptive repair proc-
ess that leads to the development of BPD is complex with
a great many factors that interplay to determine outcome.
It is very likely that other genetic play a role in determin-
ing the risk of poor outcome. Polymorphisms in
cytokines, their receptors, bacterial pattern recognition
molecules, surfactant proteins, and heme oxygenase-1 are
known to alter the course of other pulmonary diseases
and should be examined as to their potential role in the
development of BPD in the premature infant.
Conclusions
The ACE I/D polymorphism does not significantly influ-
ence the development of BPD in ventilated infants less
than 1250 grams.
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